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ABSTRACT:
Fibrates are a group of hypolipidemic agents which efficiently lower serum
triglyceride levels by affecting the expression of many genes involved in lipid
metabolism. These effects are exerted via the peroxisome proliferator-activated
receptor alpha (PPAR a ). In addition, fibrates also lower serum cholesterol levels,
suggesting a possible link between the PPAR a  and cholesterol metabolism. Bile
acid formation represents an important pathway for elimination of cholesterol,
and the sterol 12a -hydroxylase is a branch-point enzyme in the bile acid
biosynthetic pathway, which determines the ratio of cholic acid to
chenodeoxycholic acid. Treatment of mice for one week with the peroxisome
proliferator WY-14,643 or fasting for 24 hours both induced the sterol 12a -
hydroxylase mRNA in liver. Using the PPAR a  knockout mouse model, we show
that the induction by both treatments was dependent on the PPAR a . A reporter
plasmid containing a putative peroxisome proliferator-response element (PPRE)
identified in the rat sterol 12a -hydroxylase promoter region was activated by
treatment with WY-14,643 in HepG2 cells, being dependent on co-transfection
with a PPAR a  expression plasmid. The rat 12 a -hydroxylase PPRE bound in vitro
translated PPAR a  and RXR a , albeit weakly, in electrophoretic mobility shift assay.
Treatment of wild-type mice with WY-14,643 for one week resulted in an
increased relative amount of cholic acid, an effect which was abolished in the
PPAR a  null mice, verifying the functionality of the PPRE in vivo .
INTRODUCTION
Fibrates and their derivatives constitute a group of hypolipidemic agents
which are used in the treatment of hypertriglyceridemia and combined
hyperlipidemia. These fibrates belong to a structurally diverse group of
compounds known as peroxisome proliferators, which have been shown to cause
liver hepatomegaly, proliferation of peroxisomes and induction of many
enzymes involved in peroxisomal and mitochondrial b -oxidation and w -
oxidation of fatty acids (for review see (1)). In the past number of years, significant
progress has been made in understanding the mechanism of action of these
peroxisome proliferators. These compounds activate the peroxisome proliferator-
3activated receptor alpha (PPAR a ), a member of the nuclear hormone receptor
superfamily (2). The PPAR a  binds as a heterodimer with the retinoid X receptor
(RXR) to a peroxisome proliferator-response element (PPRE) located in the
promoter region of target genes e.g. peroxisomal acyl-CoA oxidase (ACO) (3), P450
4A1 (CYP4A1) (4), and the enoyl-CoA/3-hydroxyacyl-CoA
hydratase/dehydrogenase multifunctional enzyme (5). Targeted disruption of the
PPAR a  gene resulted in lack of peroxisome proliferation, no hepatomegaly and
lack of induction of peroxisome proliferator-regulated genes in response to
peroxisome proliferators (6-8). The PPAR a  has also been shown to play a critical
role in the adaptive response to fasting in mice (8-11) as the induction of several
genes involved in lipid catabolism is abolished in the PPAR a -null mice. In
addition to the triglyceride lowering effect, fibrates also lower plasma cholesterol
levels in humans (12). Bezafibrate treatment of normolipidemic gallstone
patients resulted in decreased levels of total, LDL- and VLDL-cholesterol, while
HDL-cholesterol was unchanged. In addition, bezafibrate treatment changed the
bile acid composition in bile with cholic acid being increased and
chenodeoxycholic acid being decreased, suggesting an involvement of the PPAR a
in the regulation of expression of sterol 12 a -hydroxylase and thereby affecting bile
acid composition.
Bile acids are formed in the liver from cholesterol and their synthesis represents
an important pathway for elimination of cholesterol from the body. The bile acid
biosynthetic pathway involves a number of enzymatic modifications of the
cholesterol backbone catalyzed by several P-450 enzymes, followed by b -oxidation
of the cholesterol side chain and conjugation of the formed bile acid to glycine or
taurine (for review see (13)). The rate limiting step in bile acid formation is
generally believed to be the 7a -hydroxylation of cholesterol, catalyzed by
cholesterol 7 a -hydrolxylase (CYP7A1). The sterol 12 a -hydroxylase (CYP8B1) is a
hepatic microsomal enzyme that acts at a branch-point in the bile acid synthetic
pathway by catalyzing the conversion of 7 a -hydroxy-4-cholesten-3-one to 7 a ,12a -
dihydroxy-4-cholesten-3-one. This conversion determines the ratio of cholic acid
to chenodeoxycholic acid, and the balance may be important in the development
of gallstones; chenodeoxycholic acid may, in contrast to cholic acid, reduce the
degree of cholesterol saturation in bile, which is of importance for cholesterol
gallstone formation. Sterol 12 a -hydroxylase is highly regulated and many of the
early studies carried out were involved in the regulation of the enzyme activity.
Clofibrate treatment increases sterol 12 a -hydroxylase activity and mRNA level in
rat liver microsomes (14,15). The enzyme was initially purified from rabbit liver
4microsomes by Ishida et al in 1992 and the activity was shown to be elevated by
several treatments including starvation and administration of streptozotocin in
rat (16). Other studies showed that following starvation, both sterol 12a -
hydroxylase enzyme activity and mRNA levels were increased in rat and mouse,
suggesting a possible transcriptional regulation in this case (17), but the
mechanism of this regulation was not understood. Recently, the structure of the
sterol 12 a -hydroxylase gene in rat, human and mouse (15,18,19) and the cDNA in
rabbit (17) have been elucidated, providing important tools for detailed studies on
the regulation of this gene.
As fibrates act as ligands for the PPAR a  and treatment with these compounds
results in an altered bile acid synthesis, we examined the effects of these
compounds on the expression of sterol 12a -hydroxylase. From in v i v o
experiements using the PPAR a -null mouse model and in vitro  experiments, we
show that the sterol 12a -hydroxylase gene is under regulation of the PPAR a ,
activation of which results in a changed bile acid composition.
EXPERIMENTAL PROCEDURES
Animals and treatment  - Ten to twelve week old wild-type or PPAR a -null
male mice on a pure Sv/129 genetic background (derived from the original
colony of mixed background mice) (6) were housed in a temperature and light
controlled environment. Mice were treated with a diet containing 0.1% (w/w)
WY-14,643 (Calbiochem-Novabiochem Intl.)  for one week or maintained on a
normal chow diet. Fasting experiments were carried out for 24 hours and animals
were sacrificed at 9.00 am. All mice had access to water ad libitum. Animals were
euthanized by CO2 asphyxiation followed by cervical dislocation, and liver and
gallbladders were excised. The liver samples were frozen in liquid nitrogen and
stored at -70oC for preparation of total RNA.
Northern blot analysis - Total RNA was isolated from mouse liver samples
using QuickPrepR Total RNA Extraction Kit (Pharmacia Biotech, Uppsala,
Sweden). Northern blot analysis was carried out as described (8) using full-length
cDNA probes corresponding to the mouse sterol 12a -hydroxylase, mouse
cholesterol 7 a -hydroxylase, rat ACO and b -actin.
Reporter gene assay system - A fragment of the 5’-flanking region of the rat
sterol 12a -hydroxylase gene containing an identified putative peroxisome
proliferator-response element (PPRE) was amplified by PCR from a clone
containing the rat gene. The fragment corresponded to bp -173 to +48 from the
transcription start site (18). The forward primer used was CTG ACC AAG CTC
5TGC TGT GTC and the reverse primer was CAG CCT CAG AGC AAG GTC CA.
The primers contained restriction sites for KpnI and MluI to facilitate cloning into
the luciferase reporter vector pGL3 Basic (pGL3 12a ). Sequences were verified
using the ABI Prism Dye Terminator Ready-Reaction Kit (Perkin Elmer).
Mutations were introduced into the PPRE by polymerase chain reaction using
QuikChange™ Site Directed Mutagenesis kit (Stratagene) using the following
primers 5’-cctcagagca    CT   GTCCAAGGGCAtgggcgtttg-3’ (pGL3 12a -M1) and 5’-
cctcagagcaAGGTCC    GC   GGGCAtgggcgtttg-3’ (pGL3 12a -M2) (mutations in the PPRE
are underlined). The presence of the mutations were confirmed by sequencing.
Cells were co-transfected with pcDNA3.1+ (Invitrogen) containing the mouse
PPAR a  cDNA as described (8). The pSV- b -galactosidase vector was used to
monitor transfection efficiency (Promega Corp., Madison, WI, USA).
Cell culture - HepG2 cells were routinely cultured in DMEM/F12 medium
(Sigma Corp) with 10% fetal calf serum, penicillin and streptomycin (100 U/ml of
each) in an atmosphere of 5% CO2. The cells were cultured in 12 well plates with
105 cells per well. The cells were grown to approximately 80% confluence before
transfection. Transfections were carried out using Tfx-20 reagent (Promega Corp.),
in a ratio of 1:3 (w/v) plasmid to reagent. Cells were transfected with 0.4 m g pGL3
Basic vector containing the sterol 12 a -hydroxylase promoter region or pGL3 Basic
vector containing mutations in the sterol 12 a -hydroxylase promoter, 0.4 m g of the
PPAR a  expression vector and 0.2 m g of the pSV- b -galactosidase control vector.
The cells were incubated for 48 hours before harvest with/without addition of 50
m M WY-14,643 in medium containing 10% delipidated calf serum (Sigma Corp.)
as indicated. Cell lysates were assayed for luciferase activity using Luciferase
Reporter Gene Assay (Promega Corp.) and for b -galactosidase activity using b -
Galactosidase Enzyme Assay System (Promega Corp.). Four to eight individual
experiments were carried out and luciferase activity was normalized to b -
galactosidase activity.
Electrophoretic Mobility Shift Assay (EMSA) - Oligonucleotides (obtained
from Cybergene AB, Novum, Huddinge) corresponding to the PPRE for the rat
acyl-CoA oxidase gene (ACO) and the putative PPRE for rat sterol 12 a -hydroxylase
were as follows: ACO - 5’-tcgagactTGACCTTTGTCCTggtc-3’; sterol 12a -
hydroxylase - 5’-cagagcaAGGTCCAAGGGCAtgggcgt-3’, with the core sequence of
the PPRE site indicated in capital letters. Mutated rat sterol 12a -hydroxylase
probes were prepared containing various nucleotide substitutions (underlined) as
follows: 5’-cctcagagca    CT   GTCCAAGGGCAtgggcgtttg-3’ (12 a -M1), 5’-
cctcagagcaAGGTCC    GC   GGGCAtgggcgtttg-3’ (12 a -M2) and    5’-
tcagagcaAGGTC    AAAGGGCAtgggt-3’ (12 a -M3). Ten pmol of each probe was
6labeled with g -32P dATP (NEN Life Science Products) using T7 polynucleotide
kinase (Boehringer Mannheim). In vitro  translated mouse PPAR a  and RXR a
were synthesized using the TNT coupled reticulocyte lysate system (Promega
Corp., Madison, WI). Gel mobility shift assay incubation mixes (25 m l) contained
10 mM Tris (pH 7.8), 20 mM KCl, 2 m g bovine serum albumin (BSA), 10% glycerol,
500 ng of poly(dI-dC).poly(dI-dC) (Pharmacia Biotech) and 1 m l of in vitro
translated PPAR a  and RXR a . In antibody supershift assays, 0.65 m l of RXR a
antibody (a gift from Dr. Pierre Chambon) was added to the reaction mix. 50,000
cpm of labeled probe was added to each reaction and incubations were carried out
for 45 minutes on ice. The complexes were resolved on a 5% polyacrylamide gel
in 1X TBE and the gel was dried and exposed to X-ray film overnight.
Bile acid analysis - Gallbladders were removed from untreated wild-type and
PPAR a -null mice and mice treated with WY-14,643 for one week. The
gallbladders were minced in saline and hydrolyzed in 1 M KOH for 4 hours at
110oC. The hydrolyzed mixture was extracted twice with diethylether to remove
neutral steroids. After acidification with hydrochloric acid, the bile acids were
extracted with diethylether. Bile acids in the ether phase were methylated by
treatment with 2,2-dimethoxypropane in acid methanol for 30 minutes at 55oC.
After removal of the solvent under N2 the material was converted into
trimethylsilyl ethers and analyzed by gas-liquid chromatography. A Hewlett
Packard 6890 gas chromatograph equipped with a 30 m, 0.25 mm i.d. fused silica
column coated with a 0.25 µm layer of cross-linked methyl silicone was used.
Statistical analysis was performed using the SPSS version 9.0 and data was
analyzed using one factor analysis of variance (ANOVA) followed by Tukey’s test.
RESULTS
Sterol 12 -hydroxylase mRNA expression is regulated via PPAR  - It has
previously been shown that sterol 12 a -hydroxylase mRNA is induced in rat liver
by the peroxisome proliferator clofibrate (15). As the effects of peroxisome
proliferators are mediated via the PPAR a  (6), we used the PPAR a -null mouse
model to examine the in vivo  regulation of sterol 12 a -hydroxylase. Feeding mice
a WY-14,643 containing diet for one week resulted in a doubling of sterol 12 a -
hydroxylase mRNA (Fig. 1A). However this upregulation was not evident in the
PPAR a -null mice which were also treated with WY-14,643, demonstrating that
the peroxisome proliferator-mediated induction of sterol 12a -hydroxylase is
dependent on the PPAR a .
7The cholesterol 7 a -hydroxylase is considered as the rate limiting enzyme in
bile acid biosynthesis, and we therefore examined the effect of WY-14,643
treatment on its expression. No apparent change by this treatment was observed
in wild-type mice. However, the expression was considerably lower in the
PPAR a -null mice, with an individual variation in expression. We also examined
the regulation of the peroxisomal acyl-CoA oxidase (ACO), the rate-limiting
enzyme in peroxisomal b -oxidation, which is widely used as a marker enzyme for
PPAR a -regulated gene expression. ACO expression was strongly elevated by
treatment of wild-type mice with WY-14,643, and this effect was also mediated via
the PPAR a  as the upregulation of mRNA expression was not evident in the
PPAR a -null mice after one week of treatment.
Several groups have shown that sterol 12 a -hydroxylase mRNA is increased
following starvation in rodents (15,17,19). Studies have shown that the PPAR a  is
involved in mediating the fasting-induced upregulation of a number of genes in
lipid metabolism (9-11) and we therefore used the PPAR a -null mouse model to
examine the mRNA level of sterol 12a -hydroxylase following fasting for 24
hours. Sterol 12a -hydroxylase mRNA expression was increased in wild-type
animals by fasting but this upregulation was not present in the PPAR a -null
animals, demonstrating that the induction by fasting is also dependent on the
PPAR a  (Fig 1B). A similar pattern of mRNA expression was also seen for ACO,
with mRNA induced approximately 3-fold by fasting for 24 hours. This induction
was also dependent on the PPAR a , as the mRNA level was not elevated in the
PPAR a -knockout mice by this treatment. In contrast to WY-14,643 treatment,
starvation increased the expression of the cholesterol 7a -hydroxylase mRNA
levels in mouse in a PPAR a -dependent manner.
In summary, the Northern blot data demonstrate that similar to ACO, the
sterol 12 a -hydroxylase gene is upregulated in the liver following treatment with
WY-14,643 or starvation, and that this regulation is dependent on the PPAR a .
Identification of a peroxisome proliferator-response element in the sterol 12 -
hydroxylase promoter region - The PPAR/RXR heterodimer recognizes a
response element with a 13 bp core sequence consisting of AGGTCA A/T
AGGTCA (a direct repeat 1 - DR1). Sequence analysis of the promoter regions of
the mouse (19) and rat sterol 12 a -hydroxylase genes (18) identified a conserved
but imperfect DR1 sequence in the promoters, located at -120 and -106 bp
respectively upstream of the ATG start site (Fig. 2A). It also appears that
additional nucleotides in the flanking region of the PPRE element are important
for PPAR a /RXR heterodimer binding. Four to seven nucleotides 5’ (20,21) of the
PPRE core sequence are important for the function of the PPAR a /RXR
8heterodimer and analysis of the rat 12a -hydroxylase PPRE flanking sequences
identified 5 out of 7 conserved bases in the 5’ extended half-site (Fig. 2B).
To determine whether the PPAR a /RXR heterodimer can bind to the DR1
element identified in the rat promoter sequence, electrophoretic mobility shift
assay was performed using in vitro  translated PPAR a  and RXR a , together with
32P-labeled oligonucleotides representing the PPRE of the ACO gene, the putative
PPRE for sterol 12 a -hydroxylase and mutated sterol 12a -hydroxylase PPREs, as
shown in Fig. 2C. Neither PPAR a  nor RXR alone bound to the labeled probes
(Fig. 3). In the presence of both PPAR a  and RXR, there was a strong binding to the
PPRE of ACO, which was further retarded using the RXR antibody. Binding,
although weak, was detectable also for the sterol 12 a -hydroxylase PPRE, which
was also retarded using the RXR antibody. In order to further characterize the
binding of PPAR a  to the 12 a -PPRE, several mutations were introduced in the
half sites of the response element. Two of the mutations introduced, 12 a -M1 and
12a -M2, abolished binding of the PPAR a /RXR heterodimer to the sterol 12a -
hydroxylase PPRE. In mutant 12a -M3, a single base substitution introduced,
which resulted in an oligonucleotide that more closely resembled a perfect DR1
element, showed a very strong binding in the presence of both PPAR a  and RXR
and which showed supershift with the RXR antibody. The strong binding by the
mutated 12 a -hydroxylase PPRE (12 a -M3) was weakly competed using 50-fold or
150-fold molar excess of unlabeled wild-type sterol 12 a -hydroxylase probe (15%
and 50% competition respectively - data not shown). These data establish that the
identified PPRE in the rat sterol 12 a -hydroxylase promoter region is capable of
binding the PPAR a /RXR heterodimer, although this PPRE appears to be weak
compared to e.g. the ACO PPRE.
The sterol 12 -hydroxylase promoter is activated via PPAR  - A 222 bp
fragment of the rat sterol 12a -hydroxylase promoter region containing the
identified PPRE was cloned upstream of a luciferase reporter gene (pGL3 12a ).
This construct was then used to examine if the putative PPRE could be activated
in a cell system by co-transfection with a PPAR a  expression vector and treatment
of cells with the peroxisome proliferator WY-14,643. HepG2 cells were transiently
transfected with the reporter constructs and as seen in Fig. 4A, reporter gene
activity was not changed significantly by treatment with WY-14,643 in the absence
of PPAR a . Following co-transfection of the reporter plasmid containing the sterol
12a -hydroxylase promoter, together with an expression vector for PPAR a ,
treatment of cells with WY-14,643 resulted in a 2.5-fold increase in promoter
activity over non-treated cells. Reporter gene constructs were also prepared
containing mutations in the PPRE, which were also used in transient transfection
9experiments. Transfection of HepG2 cells with construct pGL3 12 a -M1 resulted in
an unchanged reporter activity following treatment with WY14,643 in the
presence or absence of co-transfected PPAR a , showing that the mutated PPRE
could not be activated via PPAR a  (Fig 4B). Similar results were obtained for a
second mutant prepared (pGL3-M2) (Fig. 4C) showing no induction in reporter
gene activity by WY-14,643 in the presence of PPAR a . The data demonstrate that
the PPRE identified in the rat sterol 12 a -hydroxylase is activated by peroxisome
proliferators via the PPAR a . Notably, co-transfection with the pGL3 12 a  promoter
construct and PPAR a  resulted in a decreased promoter activity when compared to
transfection with the promoter construct alone (data not shown). This reduced
promoter activity may be explained by competition for binding with the a 1-
fetoprotein transcription factor, which has recently been shown to be involved in
expression of the sterol 12a -hydroxylase, as both PPAR a /RXR and the a 1-
fetoprotein bind to the same DNA binding site in the sterol 12a -hydroxylase
promoter region (22).
The PPAR  influences bile acid composition following treatment with WY-
14,643 - The sterol 12 a -hydroxylase activity influences the ratio of cholic acid to
chenodeoxycholic acid, and increased sterol 12 a -hydroxylase activity is expected to
result in increased cholic acid formation. We therefore determined whether the
observed increase in sterol 12a -hydroxylase expression would affect bile acid
composition. Unfortunately it was not possible to measure bile acids
quantitatively since total bile was extracted from the gallbladders, which showed
highly individual bile content. Therefore, the composition of bile acids were
determined in bile using gas chromatography (Fig. 5A). In control animals, the
predominant bile acids were cholic acid and b -muricholic acid, but also present in
smaller amounts were chenodeoxycholic, deoxycholic, ursodeoxycholic and w -
muricholic acids. b -Muricholic acid is a primary bile acid formed from
chenodeoxycholic acid in the liver, whereas deoxycholic, ursodeoxycholic and w -
muricholic acids are secondary bile acids (23). Treatment of wild-type animals
with WY-14,643 for one week resulted in an increase in the relative amount of
cholic acid (p<0.009), with the PPAR a -null animals showing no significant
change in bile acid composition following treatment with WY-14,643.
Unexpectedly the relative amount of chenodeoxycholic acid was increased
approximately 4-fold by WY-14,643 treatment in wild-type animals (p<0.001), but
this increase was accompanied by a concomitant decrease in b -muricholic acid
(p<0.001), while these changes were not evident in similarly treated PPAR a -null
animals. Thus, treatment of mice with WY-14,643 increased the relative amount
of cholic acid in a PPAR a -dependent manner, which correlated to a decrease in
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chenodeoxycholic acid plus b -muricholic acid as observed in the change in ratio
of these bile acids (Fig. 5B), indicating a physiological importance of the observed
PPAR a -dependent regulation of sterol 12 a -hydroxylase gene expression.
DISCUSSION
Fibrates are peroxisome proliferators which are widely used as hypolipidemic
drugs and which act as ligands for the PPAR a  (2,24,25). Treatment of humans
with bezafibrate causes a change in the composition of individual bile acids, with
the proportion of cholic acid being increased relative to chenodeoxycholic acid
(12), indicating that the human sterol 12 a -hydroxylase gene may be regulated by
the PPAR a . To explore this possibility, we took advantage of the PPAR a -null
mouse model. The results from in v i v o  experiments clearly showed that the
sterol 12 a -hydroxylase gene is upregulated at the mRNA level by treatment with
WY-14,643 and fasting, and that these effects are dependent on the PPAR a . If such
a regulation is of physiological relevance, an altered bile acid composition would
be expected due to treatment with WY-14,643. We therefore collected gallbladders
from wild-type and PPAR a -null mice that had been treated with WY-14,643, and
analyzed the bile acid composition. Treatment for one week with this compound
changed the bile acid composition in wild-type mice; the relative amount of
cholic acid increased from 61% to 76% and this effect was abolished in the PPAR a -
null mice. In addition, somewhat unexpectedly, the relative amount of
chenodeoxycholic acid increased in the wild-type mice from about 5% to 19%.
However, this change correlated with an observed decrease in b -muricholic acid,
which is formed from chenodeoxycholic acid by hydroxylation at the 6 b -position
and an epimerization at the 7-hydroxy position (23). The relative amount of b -
muricholic acid decreased from 26% to 4% in response to WY-14,643 treatment
and both these effects were abolished in the PPAR a -null mice. This demonstrates
that the enzymes catalyzing the hydroxylation/epimerization of b -muricholic
acid in mouse are down-regulated by WY-14,643 in a PPAR a -dependent manner.
Our data show that treatment with WY-14,643 increased the relative amount
of cholic acid, the product of the sterol 12 a -hydroxylase pathway, when compared
to the amounts of chenodeoxycholic acid and b -muricholic acid, demonstrating
that regulation of the sterol 12 a -hydroxylase gene affects the composition of the
bile. The rate limiting enzyme in bile acid biosynthesis is considered to be
cholesterol 7a -hydroxylase. The regulation of expression of this enzyme is
apparently complex and shows species differences (13). Our data shows that WY-
14,643 treatment did not alter the expression of cholesterol 7a -hydroxylase in
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mouse, and it is therefore reasonable to assume that the treatment does not
change total bile acid production to any larger extent, indicating that PPAR a
mediates a quantitative regulation of cholic acid synthesis in the mouse.
In addition to the now established involvement of the PPAR a  in regulating
gene expression in response to peroxisome proliferators, such as the fibrates, this
receptor was recently shown also to mediate the effects of fasting and diabetes on
the expression of many enzymes involved in lipid metabolism (8-11). The
findings here demonstrating that upregulation of expression of the sterol 12a -
hydroxylase and cholesterol 7a -hydroxylase genes in response to fasting, and
increased expression of sterol 12a -hydroxylase in response to WY-14,643
treatment is PPAR a -dependent, suggests that the regulatory regions of these
genes contain functional PPREs. A careful scrutiny of the available genomic
sequences for the sterol 12 a -hydroxylase revealed a putative response element for
PPAR a , conserved in the mouse and rat promoters. The sequence of the putative
PPRE conformed well to the consensus sequence for PPRE with only one
nucleotide in each half site being different from a perfect DR1. In addition, 5 out
of the 7 nucleotides in the 5’-flanking region, which have been shown to be
important for PPAR a  binding, conformed to the consensus (20,21). The
functionality of the rat PPRE was verified in cell culture experiments, showing
that a reporter gene containing the PPRE was activated by addition of WY-14,643
only in the presence of co-transfected PPAR a . Mutations introduced into the
PPRE resulted in lack of induction by WY-14,643 in the presence of PPAR a .
Recently del-Castillo-Olivares et al (22) showed that the a 1-fetoprotein
transcription factor is required for the expression of sterol 12 a -hydroxylase. The
a 1-fetoprotein binding site identified by this group is in fact the same site as the
PPRE now identified by us. Notably, the mutations which we introduced into the
PPRE resulted in a substantially lower promoter activity than the wild-type
promoter (approximately 95% lower), which could be explained by a distrubance
in the binding site for a 1-fetoprotein transcription factor. During our transfection
experiments, a decreased promoter activity was obtained with co-transfection of
PPAR a  and the sterol 12 a -hydroxylase promoter, and this could also be explained
by competition between PPAR a  and the a 1-fetoprotein transcription factor for the
same binding site.
Direct binding of PPAR/RXR heterodimer to the PPRE was verified in EMSA
experiments, but binding was weak compared to binding to the rat ACO PPRE
probe. However, mutation of the PPRE (mutants 12 a -M1 and 12 a -M2) completely
abolished binding. In contrast, one mutated oligonucleotide generated (12 a -M3)
containing a single base substitution in the PPAR a -binding half-site, had a
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profound effect on the binding; the mutated sterol 12 a -hydroxylase PPRE was as
efficient as the ACO PPRE and the wild-type sterol 12 a -hydroxylase probe acted as
a weak competitor for binding. The weak binding properties of the sterol 12a -
hydroxylase PPRE is however in line with the in  v ivo  data; expression of the
sterol 12 a -hydroxylase gene is only increased about 2-fold in response to WY-
14,643 treatment of mice, while ACO is strongly induced. Notably, the PPAR a -
mediated increase in sterol 12 a -hydroxylase expression by fasting is at least as
strong as the effect of WY-14,643, suggesting that the 12 a -hydroxylase gene may be
under nutritional regulation in  v ivo . As fatty acids and fatty acid derivates are
natural ligands of PPAR a , a number of metabolic processes generating increased
levels of non-esterified fatty acids, i.e. fasting and diabetes, may result in
production of bile with a larger content of cholic acid (more hydrophobic), which
could enhance resorption of sterols and long chain fatty acids from the intestine.
On the other hand, administration of fibrates to humans causes a decreased
activity of the cholesterol 7 a -hydroxylase which may result in decreased bile acid
formation and increased cholesterol saturation and a subsequent increased risk of
gallstone formation (12,26,27).
The important roles of the nuclear receptors farnesoid X receptor (FXR) and
the liver X receptor alpha (LXR a ) in regulation of bile acid metabolism have
recently been demonstrated (28,29). The transcription of the genes encoding
cholesterol 7a -hydroxylase and ileal bile acid binding protein appears to be
regulated by the interaction of these receptors with specific response elements in
the 5’-flanking regions of the genes (30,31). Our data demonstrate the
involvement of another nuclear receptor, the PPAR a , in the regulation of bile
acid metabolism. It appears that the PPAR a  plays a dual role in regulation of fatty
acid metabolism as well as in regulation of cholesterol metabolism by modulating
expression of enzymes involved in the biosynthesis of bile acids.
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FIGURE LEGENDS:
Fig. 1: Effects of treatment with WY-14,643 and fasting on mRNA expression in
mouse liver. (A) PPAR a -null mice (-/-) or age matched wild-type mice (+/+) were
treated with a diet containing 0.1% WY-14,643 for one week, while control
animals had access to normal chow diet ad libitum. Mice were sacrificed and total
RNA was isolated from liver. Northern blot analysis was carried out on 20 m g
RNA using a -32P-labeled cDNA probes for sterol 12 a -hydroxylase, cholesterol 7 a -
hydroxylase, acyl-CoA oxidase (ACO) and b -actin as described in Experimental
procedures. (B) Groups of six PPAR a -null mice (-/-) or age matched wild-type
mice (+/+) were fasted for 24 hours, while control animals had access to normal
chow diet ad libitum. Mice were sacrificed and total RNA was isolated from liver.
Northern blot analysis was carried out on 20 m g RNA using a -32P-labeled cDNA
probes for sterol 12 a -hydroxylase, cholesterol 7 a -hydroxylase, ACO and b -actin as
described in Experimental procedures. A representative blot with two samples per
group is shown.
Fig. 2: The peroxisome proliferator-response element in sterol 12 -hydroxylase is
conserved in rat and mouse promoter regions. (A) Alignment of 200 bp of the
promoter regions of rat and mouse sterol 12 a -hydroxylase gene. The identified
peroxisome proliferator-response element (PPRE) is boxed and the extended half-
site sequences in the 5’ flanking region are underlined. The identified
transcription start sites previously determined (18,19) are indicated in the rat and
mouse sequences by filled triangles. The ATG start site is boxed with double lines.
(B) The core consensus sequence for the PPRE (DR1) is indicated together with the
5’flanking region. The nucleotide sequence for the identified PPREs in rat sterol
12a -hydroxylase and rat ACO are shown. (C) The nucleotide sequence for the rat
sterol 12 a  hydroxylase is shown. The mutated PPREs 12 a -M1, 12 a -M2 and 12 a -M3
are shown with the mutated bases underlined.           
Fig. 3: Electrophoretic mobility shift assay of the ACO and sterol 12 -hydroxylase
peroxisome proliferator-response elements. Electrophoretic mobility shift assay
(EMSA) was carried out using in vitro  translated PPAR a  and RXR a . Labeled
probes for the PPREs for rat acyl-CoA oxidase (ACO), rat sterol 12 a -hydroxylase
(12 a ) and three mutated PPRE probes for sterol 12 a -hydroxylase (12 a -M1, 12 a -M2
and 12 a -M3) were used. Supershift experiments were carried out using an RXR
antibody (Ab). The PPAR a /RXR a  heterodimer is indicated by the lower arrow,
while the supershift bands are indicated by the upper arrow.
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Fig. 4: Activation of the sterol 12 -hydroxylase peroxisome proliferator-response
element (PPRE) in vitro. HepG2 cells were transfected with a 222 bp fragment of
the rat sterol 12 a -hydroxylase 5’-flanking region containing the putative PPRE
fused upstream of a luciferase reporter gene: (A) pGL3 12 a  (B) pGL3 12 a -M1 (C)
pGL3 12 a -M2 were used for transfections. Transfected cells were treated with 50
m M WY-14,643 in the presence or absence of an expression vector for PPAR a . The
luciferase activity was normalized to b -galactosidase activity and the normalized
activity in the absence of treatment with WY-14,643 was set to 1. Data shown are
mean ± S.E.M of 4 (B and C) to 8 (A) different experiments.
Fig. 5: PPAR  influences bile acid composition following treatment with WY-
14,643. Wild-type mice (+/+) or PPAR a -null mice (-/-) were treated with a diet
containing 0.1% WY-14,643 (WY) for one week, while control animals had free
access to normal chow diet. The mice were sacrificed and the gallbladders were
excised. Bile acid composition of bile was determined using gas-chromatography.
(A) Relative distribution (%) of bile acids. CA, cholic acid: CDCA,
chenodeoxycholic acid: b -MCA, b -muricholic acid: DCA, deoxycholic acid: UDCA,
ursodeoxycholic acid: w -MCA, w -muricholic acid. (B) Ratio of primary bile acids,
cholic acid versus chenodeoxycholic + b -muricholic acid. * p < 0.011.
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